Thursday 19 April 2012 - Register Now

Amakem (BEL)

Amakem was founded in 2010 to develop safe and effective kinase based therapies for diseases with an inflammatory component such as glaucoma, COPD, IBD and several skin diseases. The company's proprietary Localized Drug Action principle and its highly selective kinase inhibitors are key to the developing safe and effective drugs.